Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 96Pancreatic Neoplasms 85Carcinoma, Non-Small-Cell Lung 79Ovarian Neoplasms 52Fallopian Tube Neoplasms 48Triple Negative Breast Neoplasms 42Lung Neoplasms 32Neoplasm Metastasis 27Squamous Cell Carcinoma of Head and Neck 23Neoplasms 19Breast Neoplasms, Male 18Endometrial Neoplasms 17Uterine Cervical Neoplasms 16Stomach Neoplasms 16Melanoma 16Brenner Tumor 16Carcinoma, Ovarian Epithelial 15Esophageal Neoplasms 14Adenocarcinoma of Lung 13Inflammatory Breast Neoplasms 11Cholangiocarcinoma 10Adenocarcinoma, Bronchiolo-Alveolar 9Urinary Bladder Neoplasms 8Unspecified Adult Solid Tumor, Protocol Specific 8Oropharyngeal Neoplasms 8Carcinoma, Transitional Cell 8Adenocarcinoma Of Esophagus 8Mouth Neoplasms 7Colorectal Neoplasms 7Adenocarcinoma 7

Interventions

camrelizumab 4apatinib 2Oxaliplatin 2XELOX 1Taxes 1Surgical Procedures, Operative 1S 1 (combination) 1Nivolumab 1Laparoscopy 1Gastrectomy 1Conversion to Open Surgery 1Chemoradiotherapy 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Gastric Cancer × Taxes × Clear all
NCT05524974 2022-09-01

Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes

Fujian Medical University

Phase 2 Not yet recruiting
203 enrolled
Gastrointestinal

Locally Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡